Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price dropped 1.1% during mid-day trading on Tuesday . The stock traded as low as $25.60 and last traded at $25.60. Approximately 8,542,346 shares were traded during trading, a decline of 77% from the average daily volume of 37,594,320 shares. The stock had previously closed at $25.87.
A number of equities analysts have commented on PFE shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They set an "underperform" rating and a $25.00 target price for the company. Guggenheim reissued a "buy" rating and issued a $33.00 price target on shares of Pfizer in a report on Monday. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Finally, Bank of America reiterated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $31.92.
Read Our Latest Stock Report on PFE
The stock has a market capitalization of $145.28 billion, a P/E ratio of 18.18, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $26.28 and a two-hundred day moving average price of $27.63.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 earnings per share. Pfizer's revenue was up 24.7% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.71%. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is 121.99%.
Hedge funds and other institutional investors have recently modified their holdings of the business. Wells Trecaso Financial Group LLC raised its holdings in Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock worth $416,000 after purchasing an additional 350 shares in the last quarter. Washington Trust Advisors Inc. increased its stake in shares of Pfizer by 0.7% in the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company's stock worth $1,424,000 after acquiring an additional 360 shares in the last quarter. PSI Advisors LLC lifted its position in Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 385 shares during the period. Western Pacific Wealth Management LP boosted its stake in Pfizer by 10.5% during the third quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company's stock worth $118,000 after acquiring an additional 386 shares in the last quarter. Finally, Waddell & Associates LLC grew its holdings in Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock worth $723,000 after purchasing an additional 388 shares during the period. Institutional investors own 68.36% of the company's stock.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.